Privately-held, Bordeaux, France-based TreeFrog Therapeutics, which specializes in stem cell-derived therapies, recently closed on a $75 million financing round. Funds will be used to deploy biomimetic C-StemTM technology for clinical-grade manufacturing, at two new TreeFrog locations in Boston, and Kobe, Japan.

Researchers from the National Cancer Research Center (CNIO) and Massachusetts General Hospital have developed new approaches including machine learning and high-throughput microscopy to visualize DNA repair in detail and have identified new repair proteins. The findings may pave the way for new cancer therapies.

A life sciences IT expert proclaims that the age of unlimited data storage is over, and that it’s time for scientists to take data management seriously

Pfizer’s COVID-19 treatment, Paxlovid, has received emergency use authorization (EUA) by the FDA. The drug, which can be taken orally in the form of a pill, is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients over 12. Eligible patients need to have a positive COVID-19 test and be at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is available by prescription only and is recommended to be started as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

The Benjamin Franklin Institute of Technology (BFIT) partnered with Ginkgo Bioworks to develop an associate degree in biotechnology manufacturing. The program will be housed at the Nubian Square Life Science Training Center, a collaboration of organizations working to meet the demand for a well-trained and diverse life sciences workforce, with additional funding through a $100,000 grant from Kargman Family Foundation.

After a blockbuster two years bolstered by sales of its multiple COVID-19 diagnostics, Quidel is looking for a way to reinvest that windfall back into the business—and seems to have found it in the purchase of fellow test maker Ortho Clinical Diagnostics.

BridgeBio’s shot at entering a competitive market for a rare heart condition narrowed Monday after a “baffling” result in a phase 3 clinical trial where placebo patients bested those who received the treatment in a walk test.

Roche has secured its first FDA emergency green light for a rapid, over-the-counter COVID-19 test, as the U.S. government looks to boost at-home screenings in the face of the spreading omicron variant.

One antitrust probe down, one more to go.

Gyroscope Therapeutics has been spun this way and that in 2021, going from a $148 million raise to a failed IPO to a $40 million investment from Sanofi in quick succession. But Novartis has ensured the gene therapy startup has ended the year at the top of its arc by inking a $1.5 billion buyout.